Meeting
2013 ASCO Annual Meeting
Is there an interaction between epidermal growth factor receptor (EGFR) inhibition and p16-status in patients (pts) with oropharyngeal squamous cell cancer: A retrospective analysis.
Authors
Tobenna Igewonu Nwizu
Cleveland Clinic Foundation, Cleveland, OH
Tobenna Igewonu Nwizu , Lisa A. Rybicki , Deborah Chute , Cristina P. Rodriguez , Shlomo A. Koyfman , John Greskovich , Jerrold P. Saxton , Joseph Scharpf , Robert Lorenz , Brian Burkey , Benjamin J. Wood , Mumtaz Khan , Samer Al-khudari , Aaron P. Hoschar , Denise I. Ives , Joanna Bodmann , David J. Adelstein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Head and Neck Cancer
Track
Head and Neck Cancer
Sub Track
Head and Neck Cancer
Clinical Trial Registration Number
NCT00352105
Citation
J Clin Oncol 31, 2013 (suppl; abstr 6061)
DOI
10.1200/jco.2013.31.15_suppl.6061
Abstract #
6061
Poster Bd #
13A
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Induction chemotherapy with nanosomal docetaxel lipid suspension (NDLS), cisplatin, and fluorouracil in patients with locally advanced head and neck squamous cell carcinoma.
First Author: Ghanashyam Biswas
Poster
2023 ASCO Annual Meeting
Oral NRC-2694-A in combination with paclitaxel as therapy for recurrent and/or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) that progressed on or after an immune checkpoint inhibitor (ICI): A multi-center, single-arm, phase 2 trial.
First Author: Douglas Adkins
Poster
2023 ASCO Annual Meeting
Phase II prospective trial of induction chemotherapy for advanced sinonasal squamous cell or poorly differentiated carcinoma.
First Author: Kevin J. Contrera